CALT Stock CALT is expected to report earnings to rise+86% to -3 cents per share on August 13

A.I.dvisor
at Tickeron.com
05/22/24
Loading...
CALT - Calliditas Therapeutics AB
Calliditas Therapeutics AB Earnings Graph
Q2'24
Est.
$-0.03
Q1'24
Missed
by $0.01
Q4'23
Beat
by $0.12
Q3'23
Beat
by $0.10
Q2'23
Missed
by $0.06
The last earnings report on March 31 showed earnings per share of -20 cents, missing the estimate of -19 cents. P/B Ratio (18.450) is normal, around the industry mean (12.569). P/E Ratio (0.000) is within average values for comparable stocks, (153.722). CALT's Projected Growth (PEG Ratio) (0.000) is very low in comparison to the industry average of (1.431). Dividend Yield (0.000) settles around the average of (0.066) among similar stocks. P/S Ratio (5.118) is also within normal values, averaging (240.014). With 3.87K shares outstanding, the current market capitalization sits at 589.65M.
View a ticker or compare two or three
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a provider of pharmaceutical products for patients with niche indications

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
Kungsbron 1, D5
Phone
+46 84113005
Employees
86
Web
https://www.calliditas.se